PROCEPT BioRobotics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRCT research report →
Range $19 – $30
Price Chart
About the company
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH).
- CEO
- Larry L. Wood
- IPO
- 2021
- Employees
- 888
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on PRCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.42B
- P/E
- -12.75
- Fwd P/E
- 38.59
- PEG
- 0.49
- P/S
- 4.21
- P/B
- 4.49
- EV/EBITDA
- -12.98
- Div Yield
- 0.00%
- Gross Margin
- 64.66%
- Op Margin
- -33.61%
- Net Margin
- -32.60%
- ROE
- -33.23%
- ROIC
- -29.16%
Latest fiscal year · YoY change
- Revenue
- $308.05M+37.2%
- Gross Profit
- $196.23M+43.1%
- Op Income
- $-103,859,000
- Net Income
- $-95,572,000-4.5%
- EPS
- $-1.72+1.7%
- OCF Growth
- +50.6%
- FCF Growth
- +43.7%
- 52W High
- $38.11
- 52W Low
- $16.66
- 50D MA
- $19.78
- 200D MA
- $22.82
- Beta
- 0.84
- RSI (14)
- 75
- Avg Volume
- 1.30M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PROCEPT delivered 18% revenue growth in Q3, with HYDROS adoption, replacement sales, and disciplined pricing driving a higher full-year outlook and an early path to positive Q4 adjusted EBITDA.· November 4, 2026
- Q3 revenue was $98.3 million, up 18% year over year, with U.S. revenue of $85.8 million and international revenue of $12.5 million, up 32%.
- U.S. procedures topped 13,400, up 22% year over year, while gross margin was 66% versus 65% last year.
- HYDROS remained the key growth driver: 62 systems were placed in the quarter, including 20 replacements, and management said HYDROS accounts had procedure volumes more than 35% higher than legacy AQUABEAM accounts.
- Management raised confidence in the replacement cycle and said it now expects 50 to 60 replacement sales in 2026 at about $315,000 average selling price.
- Full-year guidance was reaffirmed: revenue of $390 million to $410 million, international revenue of $50 million to $51 million, about 54,000 procedures, and adjusted EBITDA loss of $35 million to $30 million, implying positive Q4 adjusted EBITDA.
Total revenue in Q3 2026 was $98.3 million, up 18% year over year. U.S. revenue was $85.8 million, up 16%, and international revenue was a record $12.5 million, up 32%. U.S. procedures were more than 13,400, up 22% year over year. U.S. handpiece and consumable revenue was $53.9 million, up 21%, with handpiece ASP around $3,570 and a handpiece-to-procedure ratio of approximately 106% versus 98% in the prior quarter. U.S. system revenue was $24.7 million, flat year over year, and the company shipped 62 HYDROS systems at an average selling price of about $495,000; 20 were replacement systems. Gross margin was 66% versus 65% in the prior-year period. Operating expenses were $92.5 million versus $77.2 million, net loss was $26.5 million versus $21.4 million, and adjusted EBITDA loss was $9.8 million versus $7.4 million. Cash, cash equivalents and restricted cash were $221.4 million at September 30, 2026. For 2026, management reiterated revenue guidance of $390 million to $410 million, international revenue of $50 million to $51 million, procedures around 54,000, gross margin of about 65% in Q4, operating expenses of $359 million to $363 million, and adjusted EBITDA loss of $35 million to $30 million. They also said Q4 adjusted EBITDA should be positive, roughly $3 million to $9 million, and that 2027 revenue growth of about 20% is a starting point for planning.
Larry Wood emphasized execution against the year’s priorities, especially the shift from legacy AQUABEAM to HYDROS, launch-team support for new placements, and the growing replacement cycle. He said the company’s commercial foundation is now in place, the organization is focused on execution, and the current pace of upgrades validates HYDROS’s differentiation. His tone was confident and upbeat, particularly around durable growth, clinical evidence, and the opportunity to expand into new markets and potentially prostate cancer.
Kevin Waters focused on the quarter’s financial discipline and the bridge to profitability. He highlighted 66% gross margin, higher operating expenses tied to commercial, clinical and product investments, and cash of $221.4 million. He also gave specific forward markers: Q4 gross margin around 65%, full-year operating expenses of $359 million to $363 million, adjusted EBITDA loss of $35 million to $30 million for 2026, and Q4 adjusted EBITDA of roughly positive $3 million to $9 million. He said pricing should stay relatively consistent near current levels, replacement ASP is expected around $315,000, and 2027 is being planned around about 20% revenue growth with some operating leverage improvement.
Analysts pressed on competition, procedure softness versus expectations, the sustainability of HYDROS utilization, and what 2027 assumptions imply. Management said competitive dynamics had not materially changed, attributed the quarter’s lighter procedure trend to typical summer seasonality and timing, and said September strengthened into Q4. They also clarified that 2027’s roughly 20% revenue growth is a base case that mostly assumes a stable capital environment and a mix shift toward HYDROS, not major upside from new initiatives or cancer.
The bull case from this call is that HYDROS adoption is gaining traction, with higher utilization than legacy systems and a growing share of the installed base. Replacement demand was far stronger than management initially expected, pricing remained disciplined, and the company still expects to exit 2026 with positive adjusted EBITDA in Q4. Management also signaled continued clinical momentum and long-term growth opportunities beyond BPH.
The main risks are that Q3 procedures came in a bit lighter than expected and management still sees seasonality and timing effects in the business. The company is also still carrying the drag from legacy AQUABEAM accounts, and management said 2027 base-case growth does not assume upside from patient activation, launch-team initiatives, or cancer. Expenses are still rising, so profitability depends on revenue growth and continued execution on pricing, utilization, and system placements.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 57.54M
- Float Shares
- 54.87M
of shares held by institutions
270 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 5.20M | ▼ 3.14K |
| Blackrock, Inc. | 4.85M | ▼ 23.07K |
| T. Rowe Price Investment Management, Inc. | 3.28M | ▲ 11.20K |
| Bnp Paribas Asset Management Holding S.A. | 2.79M | ▼ 37.68K |
| Vanguard Portfolio Management LLC | 2.47M | ▼ 61.47K |
| Vanguard Capital Management LLC | 2.41M | ▼ 48.15K |
| Jpmorgan Chase & Co | 1.91M | ▲ 1.63M |
| Frontier Capital Management Co LLC | 1.85M | ▲ 761.65K |
| State Street Corp | 1.69M | ▲ 77.08K |
| Geode Capital Management, LLC | 1.33M | ▼ 150.39K |
| Price T Rowe Associates Inc | 1.33M | ▼ 4.28K |
| Janus Henderson Group Ltd. | 1.32M | ▲ 1.32M |
Held by 262 ETFs
Biggest fund positions in PRCT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Sharma Pooja | sell | 4,710 |
| Oct 2, 26 | Mack Michael | other | 12,191 |
| Oct 2, 26 | Mack Michael | other | 7,727 |
| Oct 2, 26 | Mack Michael | other | 0 |
| Sep 9, 26 | Nouri Alaleh | sell | 297 |
| Sep 9, 26 | Templin Barry L | sell | 373 |
| Sep 9, 26 | Waters Kevin | sell | 373 |
| Aug 13, 26 | Nouri Alaleh | other | 22,965 |
| Aug 13, 26 | Nouri Alaleh | other | 31,773 |
| Aug 13, 26 | Templin Barry L | other | 26,246 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRCT coverage
Recent articles, reports, and earnings notes.
No research on PRCT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRCT report →PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026
globenewswire.com · Nov 18
PROCEPT BioRobotics Q3 Earnings Call Highlights
marketbeat.com · Nov 5
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 4
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
globenewswire.com · Nov 4
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com · Oct 28
Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); GoDaddy Inc. (NYSE: GDDY); Hub Group, Inc. (NASDAQ: HUBG); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf
globenewswire.com · Oct 27
PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth
seekingalpha.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.